Table 4.
Prognostic value of miR-1908 in different diseases.
| Disease | Type of miRNA | Sample | Prognosis of miR-1908 over-expression | Prognosis type | Reference |
|---|---|---|---|---|---|
| Breast cancer | miR-1908-3p | 60 patients (GSE33447) | poor | OS | (37) |
| Cervical cancer | miR-1908-5p | 36 patients (GSE63514) | poor | OS | (26) |
| Glioma | miR-1908-5p | 206 patients from TCGA database | poor | OS, DFS | (13) |
| miR-1908-5p | 24 Grade III and 50 Grade IV patients (GSE4412) | good | OS | (14) | |
| miR-1908-5p | 47 patients | poor | DFS | (8) | |
| NSCLC | miR-1908-5p | 76 patients | good | 5YSR | (23) |
| OC | miR-1908-5p | 491 patients from TCGA database | good | OS, DFS | (79) |
| HGSOC | miR-1908-5p | 175 patients (GSE106817) | poor | OS, PFS | (28) |
| Osteosarcoma | miR-1908-5p | 212 patients | poor | OS, DFS | (12) |
| miR-1908-5p | 46 patients | poor | OS | (9) |
NSCLC, non-small cell lung cancer; OC, ovarian cancer; HGSOC, high-grade serous ovarian carcinoma; GEO, the Gene Expression Omnibus; TCGA, the Cancer Genome Atlas; NCBI, National Center for Biotechnology Information; OS, overall survival; DFS, disease-free survival; 5YSR, 5-year survival rate; PFS, progression-free survival.